Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies

Cancer Cytopathology

Volumn 120, Issue 4, 2012, Pages 230-237

  Fujiwara, Mika ^a   Kwok, Shirley ^a   Yano, Hirohisa ^b   Pai, Reetesh K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arginase 1; Fine needle aspiration biopsy; Glypican 3; Hepatocellular carcinoma; HepPar 1

Indexed keywords

ARGINASE 1; CD34 ANTIGEN; CELL ANTIBODY; FORMALDEHYDE; GLYPICAN 3; HEPATOCYTE PARAFFIN ANTIBODY; PARAFFIN; RETICULIN; UNCLASSIFIED DRUG; ARGINASE; GLYPICAN; TUMOR MARKER;

ARTICLE; BILE DUCT CARCINOMA; BREAST ADENOCARCINOMA; CELL DIFFERENTIATION; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; EMBEDDING; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH CARCINOMA; TISSUE FIXATION; UTERUS CARCINOMA; ADENOCARCINOMA; BREAST TUMOR; COLORECTAL TUMOR; CYTODIAGNOSIS; ENZYME IMMUNOASSAY; FEMALE; LIVER TUMOR; METABOLISM; METASTASIS; NEEDLE BIOPSY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; ARGINASE; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; CYTODIAGNOSIS; FEMALE; GLYPICANS; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84868254770     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21190     Document Type: Article

References (26)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118-1127.
3. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009;15:1301-1314.
4. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33: 1175-1181.
5. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol. 2002;26:978-988.
6. Kakar S, Muir T, Murphy LM, Lloyd RV, Burgart LJ. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol. 2003;119:361-366.
7. Kakar S, Gown AM, Goodman ZD, Ferrell LD. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med. 2007;131:1648-1654.
8. Wang L, Vuolo M, Suhrland MJ, Schlesinger K. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol. 2006;50:257-262.
9. Fan Z, van de Rijn M, Montgomery K, Rouse RV. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137-144.
10. Leong AS, Sormunen RT, Tsui WM, Liew CT. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology. 1998;33:318-324.
11. Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009; 16:125-129.
12. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican- 3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008; 21:1011-1018.
13. Aviel-Ronen S, Lau SK, Pintilie M, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21:817-825.
14. Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575.
15. Zynger DL, Everton MJ, Dimov ND, Chou PM, Yang XJ. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008;130:224-230.
16. Esheba GE, Pate LL, Longacre TA. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol. 2008;32:600-607.
17. Hishinuma M, Ohashi KI, Yamauchi N, et al. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma. Histopathology. 2006;49: 479-486.
18. Yan BC, Gong C, Song J, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34:1147-1154.
19. Choi S, Park C, Ahn M, Lee JH, Shin T. Immunohistochemical study of arginase 1 and 2 in various tissues of rats. Acta Histochem. [published online ahead of print October 3, 2011.]
20. Theise ND, Curado MP, Franceschi S, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumors of the Digestive System. Lyon, France: IARC Press; 2010:205-216.
21. Shafizadeh N, Kakar S. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques. Adv Anat Pathol. 2011;18:438-445.
22. Pai RK, West RB. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. Appl Immunohistochem Mol Morphol. 2009;17:202-206.
23. Niemann TH, Hughes JH, De Young BR. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma. Cancer. 1999;87:295-298.
24. Proca DM, Niemann TH, Porcell AI, DeYoung BR. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. Appl Immunohistochem Mol Morphol. 2000;8:120-125.
25. Porcell AI, De Young BR, Proca DM, Frankel WL. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol. 2000;13:773-778.
26. Morrison C, Marsh W Jr, Frankel WL. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol. 2002;15:1279-1287.